je.st
news
Bio-Path Holdings To Initiate Development Of Liposomal Bcl-2 In Follicular Lymphoma
2014-12-29 02:22:44| drugdiscoveryonline Home Page
Bio-Path Holdings, Inc., (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, recently announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma
Tags: development
holdings
initiate
lymphoma
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||